¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antiparietal cell antibody"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® antiglobulin antibody ÇÑ±Û Çױ۷κҸ°Ç×ü
¼³¸í   
  Ç×ü¿¡ ´ëÇÑ Ç×ü, Áï Æ¯Á¤ Ç×ü¿Í °áÇÕÇÒ ¼ö Àִ Ç×ü. ´ë°³ Àΰ£ÀÇ Ç×ü¸¦ Áã¿¡ ÁÖ»çÇÏ¿© Áã·Î ÇÏ¿©±Ý Àΰ£ Ç×ü¿¡ ´ëÇÑ Ç×ü¸¦ ¸¸µé°Ô ÇÑ´Ù(Áã¿¡ À־´Â Àΰ£ÀÇ Ç×üµµ ¿ÜºÎ¿¡¼­ µé¾î¿Â ¹°ÁúÀ̹ǷÎ). À̰ÍÀº ¿©·¯ °¡Áö ½ÇÇè¿¡¼­ Àΰ£ÀǠƯÁ¤Ç×ü¸¦ °ËÃâÇϴµ¥ ÀÌ¿ëÇÑ´Ù.
¿µ¹® antibody ÇÑ±Û Ç×ü
¼³¸í   
  »ç¶÷ÀÇ ¸ö¿¡¼­ ¸é¿ª¿¡ °ü°èÇϴ ¹°Áú. ¿ÜºÎ¿¡¼­ µé¾î¿Â ¹°Áú°ú ²À ¸Â°Ô °áÇÕÀ» ÇÏ¿©¼­ ±× ¹°ÁúÀÇ »ý¹°ÇÐÀû È°µ¿À» ¾ïÁ¦Çϰųª ÆÄ±«Çϰųª »ç¶÷ÀÇ ´Ù¸¥ ¸é¿ª¼¼Æ÷·Î ÇÏ¿©±Ý °ø°ÝÇϱ⠿ëÀÌÇÏ°Ô ÇØÁִ ±â´ÉÀ» °¡Áö°í ÀÖ´Ù. Ç×ü´Â ¸é¿ª±Û·ÎºÎ¸°À̶ó´Â °ÍÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ°í ±× ÇüÅ¿¡ µû¶ó IgA, IgE, IgG, IgDµîÀ¸·Î ³ª´«´Ù.
¿µ¹® muscle cell(=muscle fiber) ÇÑ±Û ±ÙÀ°¼¼Æ÷
¼³¸í   
  ±ÙÀ°Àº ¼öÀDZÙ(ÀǽĿ¡ ÀÇÇØ¼­ Á¶ÀýÀÌ °¡´ÉÇÑ ±ÙÀ°: ¿¹¸¦ µé¾î ´Ù¸®, ÆÈ, ¾ó±¼±ÙÀ° µî)°ú ºÒ¼öÀDZÙ(Àǽİú ¹«°üÇϰԠÁ¶ÀýÇÏÁö ¾Ê¾Æµµ ¿òÁ÷À̴ ±ÙÀ°: ¿¹¸¦ µé¾î ½ÉÀå±Ù, ¼ÒÈ­±â°ü¿¡ ºÐÆ÷Çϴ ±ÙÀ° µî)À¸·Î ³ª´©¾îÁö¸ç, ±ÙÀ°¼¼Æ÷ÀÇ ¸ð¾çÀº ´ÙÀ½°ú °°´Ù(¼öÀDZÙ, ºÒ¼öÀDZ٠¿Ü¿¡ ½ÉÀå¿¡ Àִ ½ÉÀå±ÙÀº ºÒ¼öÀDZٿ¡ ÇØ´çÇÏÁö¸¸ ±× ¸ð¾çÀº ¼öÀDZٰú °°¾Æ µû·Î ºÐ·ùÇÑ´Ù).
  
  ±ÙÀ°¼¼Æ÷
¿µ¹® white blood cell(WBC), leukocyte ÇÑ±Û ¹éÇ÷±¸
¼³¸í   
  Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, È¤Àº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀΠÇö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù.
¿µ¹® mast cell ÇÑ±Û ºñ¸¸ ¼¼Æ÷
¼³¸í   
  µ¿¹°ÀÇ °áÇÕ Á¶Á÷ °¡¿îµ¥ ³Î¸® ºÐÆ÷Çϴ ¼¼Æ÷. °áÇÕÁ¶Á÷°ú Á¡¸·Á¶Á÷ ³»¿¡ Àִ ȣ¿°±â¼º »ö¼Ò·Î ÀÌ¿°»ö¼º(metachromasia)À» ³ªÅ¸³»´Â °ú¸³À» °¡Áø ¹æÃßÇüÀÇ ¼¼Æ÷¿¡ ÀÛÀº µÕ±Ù ÇÙÀ» °¡Áø´Ù. ºñ¸¸¼¼Æ÷ÀǠǥ¸é¿¡´Â IgE¿¡ ´ëÇÑ ¼ö¿ëü°¡ Á¸ÀçÇϸç, ¼ö¿ëü¿¡ °áÇÕÇÑ IgE ºÐÀڵ鳢¸® ´Ù°¡ÀÇ Ç׿ø¿¡ ÀÇÇØ ¼­·Î ¿¬°áµÇ¸é ºñ¸¸¼¼Æ÷ °ú¸³Å»Ãâ ¹ÝÀÀÀÌ ÀϾ, È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ, ÇìÆÄ¸° µîÀÇ È­ÇÐÀü´Þ ¹°ÁúÀÌ ¹æÃâµÇ¾î, Áï½ÃÇü ¾Ë·¹¸£±â ¹ÝÀÀ µîÀÇ Áõ»óÀ» ÀÏÀ¸Å²´Ù. ÇǺÎ, À帷, Ç÷°ü ÁÖÀ§, Á¡¸· ÁÖº¯¿¡ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • antibody
    Ç×ü
  • antibody absorption
    Ç×üÈí¼ö
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤(¹ý)
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody removal
    Ç×üÁ¦°Å
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody
    Ç×ü
  • anti-double stranded deoxyribonucleic acid antib antibody
    Ç×ÀÌÁß°¡´Úµð¿£¿¡ÀÌÇ×ü
  • anti-dsDNA antibody
    (¢¡anti-double stranded deoxyribonucleic acid antibod) Ç×ÀÌÁß°¡´Úµð¿£¿¡ÀÌÇ×ü
  • anti-Ro antibody
    Ç׾˿ÀÇ×ü
  • anti-Sm antibody
    Ç׿¡½º¿¥Ç×ü
  • anticardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • antineutrophil cytoplasmic antibody
    Ç×Áß¼º±¸¼¼Æ÷ÁúÇ×ü
  • antinuclear antibody
    Ç×ÇÙÇ×ü
  • antiphospholipid antibody
    Ç×ÀÎÁöÁúÇ×ü
  • antisperm antibody
    Ç×Á¤ÀÚÇ×ü
  • atypical antibody
    ºñÁ¤ÇüÇ×ü
  • autoimmune antibody
    ÀÚ°¡¸é¿ªÇ×ü
  • blocking antibody
    Â÷´ÜÇ×ü
  • polyclonal antibody
    ´ÙŬ·ÐÇ×ü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • cell-associated antibody
    ¼¼Æ÷ºÎÂøÇ×ü
  • cell-bound antibody
    (¢¡cell-fixed antibody) ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • antibody
    Ç×ü
  • anaphylactic antibody
    ¾Æ³ªÇʶô½Ã½ºÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody removal
    Ç×üÁ¦°Å
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • NK cell [=natural killer cell]
    ÀÚ¿¬»ì»ó¼¼Æ÷
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • quiescent cell, Q cell
    Á¤Áö¼¼Æ÷
  • DF3 antibody
    DF3 Ç×ü
  • DL antobody => Donath-Landsteiner antibody
    DL Ç×ü
  • Donath-Landsteiner antibody
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê Ç×ü
  • FTA (fluorescent treponemal antibody)
    ¸Åµ¶Çü±¤Ç×ü °Ë»ç¹ý
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gp 120/160 antibody
    Gp 120/160 Ç×ü
  • Gp 24 antibody
    Gp 24 Ç×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • cell-associated antibody
    ¼¼Æ÷°áÇÕÇ×ü(á¬øàÌ¿ùêù÷ô÷), ¼¼Æ÷°íÁ¤Ç×ü, ¼¼Æ÷°ü ·ÃÇ×ü.
  • cell-bound antibody
    [³»°ú]¼¼Æ÷°áÇÕÇ×ü(á¬øàÌ¿ùêù÷ô÷).
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü(á¬øàÌ¿ùêù÷ô÷).
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • beta cell insulin cell
    º£Å¸¼¼Æ÷ Àν´¸°¼¼Æ÷
  • bronchiolar cell clara cell
    ¼¼±â°üÁö¼¼Æ÷
  • cell to cell cooperation
    ¼¼Æ÷°£ÇùÁ¶ÀÛ¿ë(á¬øàÊàúððàíÂéÄ).
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • clear cell basal cell carcinoma
    Åõ¸í¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷(Á¦1Çü»ç±¸¼¼Æ÷)
  • Clear cell [Epinephrine cell]
    ¹àÀº¼¼Æ÷ [¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¸í¼¼Æ÷(¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Sustentacular cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
  • Secretory epithelial cell [Glandular cell]
    ºÐºñ»óÇǼ¼Æ÷ [»ù¼¼Æ÷]
    [¿¾ ¿ë¾î] ºÐºñ»óÇǼ¼Æ÷
  • Interstitial cell [Dark cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Interstitial cell [Leydig`s cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Bronchiolar cell [Clara cell]
    ¼¼±â°üÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐºñ¼¼Æ÷
  • Parafollicular cell [Calcitonin cell]
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Neurolemmal cell [Schwann`s cell]
    ½Å°æÁý¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æÃʼ¼Æ÷
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • excretory cell
    ¹è¼³¼¼Æ÷
  • flame cell
    ºÒ²É¼¼Æ÷
  • G cell G
    ¼¼Æ÷
  • germ cell
    ¹è¼¼Æ÷
  • interstitial plasma cell pneumonia
    °£Áú¼ºÇüÁú¼¼Æ÷Æó¿°
  • nurse cell
    º¸¸ð¼¼Æ÷
  • renette cell
    ¹è¼³¼¼Æ÷
  • tegumental cell
    Ç¥ÇǼ¼Æ÷
  • vitelline cell
    ³­È²¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acquired antibody
    "ȹµæÇ×ü (üòÔðù÷ô÷), ÈÄõ¼ºÇ×ü (ý­ô¸àõù÷ô÷)"
  • agglutinating antibody
    ÀÀÁýÇ×ü(ëêó¢ù÷ô÷)
  • anti-idiotype antibody
    Ç×(ù÷)À̵ð¿ÀŸÀÌÇÁ Ç×ü(ù÷ô÷)
  • anti-immunoglobulin antibody
    Ç׸鿪(ù÷Øóæ¹)±Û·ÎºÒ¸° Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody binding fraction
    Ç×ü°áÇÕºÐȹ (ù÷ô÷Ì¿ùêÝÂüò)
  • antibody combining site
    Ç×ü°áÂø(ù÷ô÷Ì¿ó·)ÀÚ¸®
  • antibody dependent cellular cytotoxicity
    Ç×üÀÇÁ¸ÀÚ¸® ¼¼Æ÷¼º¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øààõá¬øàÔ¸àõ)
  • antibody diversity
    Ç×ü ´Ù¾ç¼º(ù÷ô÷ÒýåÆàõ)
  • antibody fixation
    Ç×ü °íÁ¤(ù÷ô÷ͳïÒ)
  • antibody formation
    Ç×ü Çü¼º(ù÷ô÷û¡à÷)
  • antibody heterogeneity
    Ç×ü ºÒ±ÕÀϼº(ù÷ô÷ÝÕгìéàõ)
  • antibody mediated hypersensitivity
    Ç×ü ¸Å°³ °ú¹ÎÁõ(ù÷ô÷ØÚ˿ΦÚÂñø)
  • antibody response
    Ç×ü ´ëÀÀ(ù÷ô÷Óßëë)
  • antibody specificity
    Ç×ü ƯÀ̼º(ù÷ô÷÷åì¶àõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agglutination antibody titer
    ÀºÁýÇ×ü¿ª°¡
  • antibody
    Ç×ü
  • antigen antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • acinar cell
    Æ÷»ó¼¼Æ÷
  • air cell
    ÇԱ⵿
  • alveolar cell carcinoma
    ÆóÆ÷¼¼Æ÷¾ÏÁ¾
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷±¸
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò, °ÇÀüÁö
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷
  • daughter cell
    µþ¼¼Æ÷, ³¶¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACA abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino...
MC mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med...
AMA against medical advice; alkaline membrane assay; American Management Association; American Medical A...
NA Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida...
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ADCC Antibody Dependent Cell Cytotoxicity
ADCC Antibody Dependent Cell-Mediated Cytotoxicity
ADCC Antibody-dependent cell-mediated cytolysis
AFC Antibody-forming cell
ICA Islet cell antibody
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • clear cell basal cell carcinoma
    Åõ¸í ¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • agglutination antibody titer
    ÀÀÁý Ç×ü ¿ª°¡
  • albumin agglutinating antibody
    ¾ËºÎ¹Î ÀÀÁý Ç×ü
  • alloimmune antibody
    µ¿Á¾ ¸é¿ª Ç×ü
  • anti-antibody
    Ç×Ç×ü
    Ç׿ø°ú °áÇÕÇÑ IgG classÀÇ Ç×ü ºÐÀڿ͸¸ °áÇÕÇÒ ¼ö ÀÖ´Â Ç×üÀÌ¸ç ºñƯÀÌÀûÀÎ ÀÀÁý IgG¿Í´Â ¹ÝÀÀÇÏÁö ¾Ê´Â Á¡¿¡¼­ ÀÌ Ç×ü´Â Ç׿ø Ç×ü °áÇÕ¹°ÀÇ °ËÃâ¿¡ ÀÀ¿ëµÇ°í ÀÖ´Ù. »ç¶÷ÀÇ ÀÚ¿¬ Ç×üÀÇ ÀÏÁ¾ÀÌ¸ç ·ù¸¶ÅäÀ̵å ÀÎÀÚÀÇ Æ¯¼öÇüÀ¸·Î º¸´Â °æÇâµµ ÀÖ´Ù.
  • anti-DNA-antibody
    Ç×-DNA Ç×ü
  • anti-intercellular substance antibody
    Ç×¼¼Æ÷°£ ¹°Áú Ç×ü
  • antibasement membrane antibody
    Ç×±âÀú¸· Ç×ü
  • antibody absorption
    Ç×ü ÈíÂø
  • antibody defect
    Ç×ü °á¼Õ
  • antibody excess zone
    Ç×ü °úÀ׿ª
  • antibody half-life
    Ç×ü ¹Ý°¨±â
    Ç×ü ºÐÀÚ°¡ Çü¼ºµÈ ÈÄ Æò±Õ »ýÁ¸ÇÏ´Â ½Ã°£À» ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î¼­, º¸Åë µ¿¹°Ã¼³»¿¡¼­ ÀÏÁ¤·®ÀÇ ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 50%¸¦ Á¦°ÅÇÏ´Â µ¥ °É¸®´Â ½Ã°£À¸·Î Ç¥½ÃÇÑ´Ù. ÀÌ ¹Ý°¨±â´Â ¸é¿ª ±Û·ÎºÒ¸°ÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antibody-dependent cell cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
(12 Dec 1998)
antibody-forming cell <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
cell-bound antibody A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region.
(05 Mar 2000)
T-cell-rich, B-cell lymphoma <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component.
See: adult T-cell lymphoma.
(05 Mar 2000)
affinity antibody The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible.
(05 Mar 2000)
agglutinating antibody 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen.
Synonym: agglutinating antibody, immune agglutinin.
2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin.
(05 Mar 2000)
anaphylactic antibody Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain.
See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test.
Synonym: anaphylactic antibody, cytophilic antibody.
(05 Mar 2000)
anti-basement membrane antibody Autoantibodies to renal glomerular basement membrane antigens.
(05 Mar 2000)
antibody An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc.
(18 Nov 1997)
antibody affinity A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
(12 Dec 1998)
antibody aldolase <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations
Registry number: EC 4.1.2.-
Synonym: fab 33f12, aldolase catalytic antibody
(26 Jun 1999)
antibody-coated bacteria test, urinary Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively.
(12 Dec 1998)
antibody combining site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antibody deficiency disease <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody
    Ç×µ¶¼Ò; Ç×ü
  • antibody
    Ç×µ¶¼Ò;(Ç÷¾× ÁßÀÇ)Ç×ü
  • monoclonal antibody
    ´ÜÀÏ Å¬·Ð Ç×ü
  • cell
    ¼¼Æ÷
  • HeLa cell
    Èú·¯ ¼¼Æ÷(¿¬±¸¿ëÀ¸·Î ¹è¾çµÇ°í ÀÖ´Â ¾Ï¼¼Æ÷ÀÇ ÀÏÁ¾)
  • blood cell
    Ç÷±¸
  • brain cell
    ³ú½Å°æ¼¼Æ÷
  • cadmium cell
    Ä«µå¹Å ÀüÁö
  • cell
    ÀÛÀº¹æ;¾ÏÀÚ(¼öµµ¿ø ºÎ¼ÓÀÇ);»ç½Ç;¿ÀµÎ¸·Áý;¹«´ý;(±³µµ¼ÒÀÇ)µ¶¹æ;(¹úÁýÀÇ)±¸¸Û;²É°¡·çÁÖ¸Ó´Ï;ÀüÁö;¼¼Æ÷;(Á¶Á÷³»ÀÇ)ÀÛÀº °øµ¿;¼¼Æ÷(°ø»ê´ç µîÀÇ);°¡½ºÅë(±â±¸ÀÇ);ºñÆ®ÀÇ ±â¾ï¼ÒÀÚ;µ¶¹æ»ìÀÌÇÏ´Ù;ÀÛÀº ¹æ¿¡ Ʋ¾î¹ÚÈ÷´Ù
  • cell body
    ¼¼Æ÷ÀÇ
  • cell cycle
    ¼¼Æ÷ÁÖ±â;ºÐ¿­ÁÖ±â
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á